In these cancers targeting CDCP1 with an ADC may not be appropriate due to unintended effects on normal epithelium, but labelled anti-CDCP1 antibodies may be of greater use as imaging agents to detect metastases, highlighting the potential of this antibody as a versatile molecular tool for cancer. Here, CDCP1 is linked to cancer.